257 related articles for article (PubMed ID: 30395230)
1. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
[TBL] [Abstract][Full Text] [Related]
2. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
3. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
[TBL] [Abstract][Full Text] [Related]
5. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
7. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.
Sun W; Zhang X; Ding X; Li H; Geng M; Xie Z; Wu H; Huang M
PLoS One; 2015; 10(5):e0125976. PubMed ID: 25973606
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis.
Mohanty S; Mohapatra P; Shriwas O; Ansari SA; Priyadarshini M; Priyadarsini S; Rath R; Sultania M; Das Majumdar SK; Swain RK; Dash R
Oncogene; 2022 Nov; 41(45):4929-4940. PubMed ID: 36182968
[TBL] [Abstract][Full Text] [Related]
9. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
10. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
Alam M; Mishra R
Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
[TBL] [Abstract][Full Text] [Related]
11. Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.
Tomita R; Sasabe E; Tomomura A; Yamamoto T
Oncol Rep; 2020 Nov; 44(5):1905-1916. PubMed ID: 32901850
[TBL] [Abstract][Full Text] [Related]
12. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
[TBL] [Abstract][Full Text] [Related]
13. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
[TBL] [Abstract][Full Text] [Related]
14. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.
Brown ME; Bear MD; Rosol TJ; Premanandan C; Kisseberth WC; London CA
BMC Vet Res; 2015 Aug; 11():206. PubMed ID: 26272737
[TBL] [Abstract][Full Text] [Related]
15. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.
Matsui Y; Watanabe J; Ikegawa M; Kamoto T; Ogawa O; Nishiyama H
Oncogene; 2008 Jul; 27(33):4603-14. PubMed ID: 18391982
[TBL] [Abstract][Full Text] [Related]
16. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
17. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
Zhao TC; Zhou ZH; Ju WT; Liang SY; Tang X; Zhu DW; Zhang ZY; Zhong LP
Cancer Sci; 2022 Feb; 113(2):478-488. PubMed ID: 34826159
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of TNF-alpha/NFkB/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma.
de Castro LR; de Oliveira LD; Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida OGG; Amorim MLM; Squarize CH; Castilho RM; de Almeida LO
J Cell Physiol; 2024 Feb; 239(2):e31164. PubMed ID: 38149816
[TBL] [Abstract][Full Text] [Related]
20. WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway.
Zhang X; Sun K; Gan R; Yan Y; Zhang C; Zheng D; Lu Y
BMC Cancer; 2024 May; 24(1):564. PubMed ID: 38711026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
